
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Alopexx Collaborates with Bharat Biotech on Anti-Microbial Vaccine AV0328
Details : The collaboration aims for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low and lower middle-income countries.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Biotech Consortia
Deal Size : Undisclosed
Deal Type : Financing
Alopexx Announces Investment from Biotech Consortia, Inc.
Details : The investment from BCI will be crucial for the advancement of AV0328, a synthetic vaccine designed to target poly N-acetyl glucosamine, and all clinical programs at Alopexx.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 06, 2024
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Biotech Consortia
Deal Size : Undisclosed
Deal Type : Financing

Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma
Details : The deal facilitates development and commercialization of DI-Leu16-IL2 in China and other parts of Asia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
March 03, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : F598
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : F598 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neisseria gonorrhoeae.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 19, 2017
Lead Product(s) : F598
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AV0328
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of AV0328 Administered to Healthy Adult Volunteers
Details : AV0328 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 03, 2016
Lead Product(s) : AV0328
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DI-Leu16-IL2 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 02, 2014
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
Details : DI-Leu16-IL2 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 11, 2013
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
